(Q38647682)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607163%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

A review of blinatumomab, a novel immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607163%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607163%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Dina J Benani

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607163%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

24 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607163%20AND%20SRC:MED&resulttype=core&format=json

Journal of Oncology Pharmacy Practice

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607163%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607163%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607163%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

639-645

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607163%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

The biology and therapy of adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Blinatumomab: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770

Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155215618770